Chugai Pharmaceutical Co., Ltd. and Cheplapharm K.K. announced that Chugai will transfer the business in Japan concerning the anti-cancer agent Tarceva tablets 25, 100, and 150 to Cheplapharm. Chugai ...

Introduction: Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, ...